Research progress of prognosis-related lncRNA molecular markers in gastric cancer

Abstract

Abstract:Researches on gene sequencing find that long non-coding RNA (lncRNA) does not encode protein, however, it participates in the biological pathway of gastric cancer and plays a certain role in the process of prognosis and outcome of gastric cancer. With the generation of gene databases and the popularity of computer algorithms, the researches on the prognosis-related lncRNA of gastric cancer are gradually increasing. The bioinformatics study of prognosisrelated lncRNA of gastric cancer can provide ideas for experimental researches. It is expected to provide evidence for the diagnosis and treatment of gastric cancer and improve prognosis by exploring more lncRNAs that are related to the prognosis of gastric cancer.

Key words:Stomach neoplasms,Prognosis,RNA, long noncoding

Liu Hui, Chang Ziwei, Zhang Qiumeng, Zhang Chao, Jing Liwei. Research progress of prognosis-related lncRNA molecular markers in gastric cancer[J]. Journal of International Oncology, 2019, 46(7): 434-438.

References

［1］邹文斌, 李兆申. 中国胃癌发病率及死亡率研究进展［J］. 中国实用内科杂志, 2014, 34(4): 408415. ［2］ Gu Y, Chen T, Li G, et al. LncRNAs: emerging biomarkers in gastric cancer［J］. Future Oncol, 2015, 11(17): 24272441. DOI: 10.2217/fon.15.175. ［3］ Thin KZ, Liu X, Feng X, et al. LncRNADANCR: a valuable cancer related long noncoding RNA for human cancers［J］. Pathol Res Pract, 2018, 214(6): 801805. DOI: 10.1016/j.prp.2018.04.003. ［4］ Xie SS, Jin J, Xu X, et al. Emerging roles of noncoding RNAs in gastric cancer: pathogenesis and clinical implications［J］. World J Gastroenterol, 2016, 22(3): 12131223. DOI: 10.3748/wjg.v22.i3.1213. ［5］ Jacob R, Zander S, Gutschner T. The dark side of the epitranscriptome: chemical modifications in long noncoding RNAs［J］. Int J Mol Sci, 2017, 18(11). pii: 2387. DOI: 10.3390/ijms18112387. ［6］潘磊, 梁炜, 付敏, 等. 长非编码RNA在消化系统肿瘤中的研究进展［J］. 国际肿瘤学杂志, 2016, 43(9): 706710. DOI: 10.3760/cma.j.issn.1673422X.2016.09.017. ［7］ Meseure D, Drak Alsibai K, Nicolas A, et al. Long noncoding RNAs as new architects in cancer epigenetics, prognostic biomarkers, and potential therapeutic targets［J］. Biomed Res Int, 2015: 320214. DOI: 10.1155/2015/320214. ［8］ Hutter C, Zenklusen JC. The Cancer Genome Atlas: creating lasting value beyond its data［J］. Cell, 2018, 173(2): 283285. DOI: 10.1016/j.cell.2018.03.042. ［9］ Ren W, Zhang J, Li W, et al. A tumorspecific prognostic long noncoding RNA signature in gastric cancer［J］. Med Sci Monit, 2016, 22: 36473657. DOI: 10.12659/MSM.901190. ［10］ Miao Y, Sui J, Xu SY, et al. Comprehensive analysis of a novel fourlncRNA signature as a prognostic biomarker for human gastric cancer［J］. Oncotarget, 2017, 8(43): 7500775024. DOI: 10.18632/oncotarget.20496. ［11］ Chen J, Wang X, Hu B, et al. Candidate genes in gastric cancer identified by constructing a weighted gene coexpression network［J］. Peer J, 2018, 6: e4692. DOI: 10.7717/peerj.4692. ［12］ Liu X, Wang J, Chen M, et al. Combining data from TCGA and GEO databases and reverse transcription quantitative PCR validation to identify gene prognostic markers in lung cancer［J］. Onco Targets Ther, 2019, 12: 709720. DOI: 10.2147/OTT.S183944. ［13］ Tian X, Zhu X, Yan T, et al. Differentially expressed lncRNAs in gastric cancer patients: a potential biomarker for gastric cancer prognosis［J］. J Cancer, 2017, 8(13): 25752586. DOI: 10.7150/jca.19980. ［14］ Yao XM, Tang JH, Zhu H, et al. High expression of lncRNA CASC15 is a risk factor for gastric cancer prognosis and promote the proliferation of gastric cancer［J］. Eur Rev Med Pharmacol Sci, 2017, 21(24): 56615667. DOI: 10.26355/eurrev_201712_14010. ［15］范志远, 刘炳亚, 朱正伦, 等. 基于基因表达谱分析的胃癌诊断及预后相关长链非编码RNA谱识别及鉴定［J］. 临床与病理杂志, 2015, (z1): S65. DOI: 10.3978/j.issn.20956959.2015.06.S092. ［16］ TorresMartínez AC, GallardoVera JF, LaraHolguin AN, et al. Claudin6 enhances cell invasiveness through claudin1 in AGS human adenocarcinoma gastric cancer cells［J］. Exp Cell Res, 2017, 350(1): 226235. DOI: 10.1016/j.yexcr.2016.11.025. ［17］ Hughes HR, Russell BJ, Mossel EC, et al. Development of a realtime reverse transcriptionPCR assay for global differention of yellow fever virus vaccinerelated adverse events from natural infections［J］. J Clin Microbiol, 2018, 56(6). pii: e0032318. DOI: 10.1128/JCM.0032318. ［18］ Saito T, Kurashige J, Nambara S, et, al. A long noncoding RNA activated by transforming growth factorβ is an independent prognostic marker of gastric cancer［J］. Ann Surg Oncol, 2015, 22 Suppl 3: S915S922. DOI: 10.1245/s1043401545548. ［19］ Nourbakhsh N, EmadiBaygi M, Salehi R, et al. Gene expression analysis of two epithelialmesenchymal transitionrelated genes: long noncoding RNAATB and SETD8 in gastric cancer tissues［J］. Adv Biomed Res, 2018, 7: 42. DOI: 10.4103/abr.abr_252_16. ［20］ Li CY, Liang GY, Yao WZ, et al. Integrated analysis of long noncoding RNA competing interactions reveals the potential role in progression of human gastric cancer［J］. Int J Oncol, 2016, 48(5): 19651976. DOI: 10.3892/ijo.2016.3407. ［21］ Zhang Y, Li H, Zhang W, et al. LASSObased CoxPH model identifies an 11lncRNA signature for prognosis prediction in gastric cancer［J］. Mol Med Rep, 2018, 18(6): 55795593. DOI: 10.3892/mmr.2018.9567. ［22］ Lacalle RA, Blanco R, CarmonaRodríguez L, et al. Chemokine receptor signaling and the hallmarks of cancer［J］. Int Rev Cell Mol Biol, 2017, 331: 181244. DOI: 10.1016/bs.ircmb.2016.09.011. ［23］ Dou C, Cao Z, Yang B, et al. Changing expression profiles of lncRNAs, mRNAs, circRNAs and miRNAs during osteoclastogenesis［J］. Sci Rep, 2016, 6: 21499. DOI: 10.1038/srep21499. ［24］ Cantini L, Medico E, Fortunato S, et al. Detection of gene communities in multinetworks reveals cancer drivers［J］. Sci Rep, 2015, 5: 17386. DOI: 10.1038/srep17386. ［25］ Gu J, Li Y, Fan L, et al. Identification of aberrantly expressed long noncoding RNAs in stomach adenocarcinoma［J］. Oncotarget, 2017, 8(30): 4920149216. DOI: 10.18632/oncotarget.17329. ［26］曹伟军, 谈路轩, 李超, 等. 利用转录组测序数据分析胃癌长链非编码RNA的研究［J］. 临床肿瘤学杂志, 2017, 22(12): 11161120. ［27］ Li Y, Li D, Zhao M, et al. Long noncoding RNA SNHG6 regulates p21 expression via activation of the JNK pathway and regulation of EZH2 in gastric cancer cells［J］. Life Sci, 2018, 208: 295304. DOI: 10.1016/j.lfs.2018.07.032. ［28］陈瑞东, 唐文, 胡端敏. 长链非编码RNA MEG3在肿瘤中的研究［J］. 国际肿瘤学杂志, 2015, 42(2): 118121. DOI: 10.3760/cma.j.issn.1673422X.2015.02.010. ［29］ Wei GH, Wang X. LncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway［J］. Eur Rev Med Pharmacol Sci, 2017, 21(17): 38503856. ［30］ Wu SW, Hao YP, Qui JH, et al. High expression of long noncoding RNA CCAT2 indicates poor prognosis of gastric cancer and promotes cell proliferation and invasion［J］. Minerva Med, 2017, 108(4): 317323. DOI: 10.23736/S00264806.17.047036. ［31］ Feng Y, Zhang Q, Wang J, et al. Increased lncRNA AFAP1AS1 expression predicts poor prognosis and promotes malignant phenotypes in gastric cancer［J］. Eur Rev Med Pharmacol Sci, 2017, 21(17): 38423849. ［32］ Wang Y, Xiao S, Wang B, et al. Knockdown of lncRNATP73AS1 inhibits gastric cancer cell proliferation and invasion via the WNT/βcatenin signaling pathway［J］. Oncol Lett, 2018, 16(3): 32483254. DOI: 10.3892/ol.2018.9040. ［33］ Zhang G, Li S, Lu J, et al. LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR92a3p in gastric cancer［J］. Mol Cancer, 2018, 17(1): 87. DOI: 10.1186/s1294301808296. ［34］ Sun M, Nie F, Wang Y, et al. LncRNA HOXA11AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1and DNMT1［J］. Cancer Res, 2016, 76(21): 62996310. DOI: 10.1158/00085472.CAN160356. ［35］ Ma P, Xu T, Huang M, et al. Increased expression of lncRNA PANDAR predicts a poor prognosis in gastric cancer［J］. Biomed Pharmacother, 2016, 78: 172176. DOI: 10.1016/j.biopha.2016.01.025.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[11]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[12]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.